{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T05:55:25Z","timestamp":1785390925814,"version":"3.55.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,12,21]],"date-time":"2019-12-21T00:00:00Z","timestamp":1576886400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,12,21]],"date-time":"2019-12-21T00:00:00Z","timestamp":1576886400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1007\/s40265-019-01247-1","type":"journal-article","created":{"date-parts":[[2019,12,21]],"date-time":"2019-12-21T08:02:42Z","timestamp":1576915362000},"page":"61-72","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["Dolutegravir\/Lamivudine Single-Tablet Regimen: A Review in HIV-1 Infection"],"prefix":"10.1007","volume":"80","author":[{"given":"Lesley J.","family":"Scott","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,12,21]]},"reference":[{"issue":"1","key":"1247_CR1","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/s40265-015-0515-6","volume":"76","author":"SE Collins","year":"2016","unstructured":"Collins SE, Grant PM, Shafer RW. Modifying antiretroviral therapy in virologically suppressed HIV-1-infected patients. Drugs. 2016;76(1):75\u201398.","journal-title":"Drugs"},{"issue":"1","key":"1247_CR2","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1177\/1060028018793252","volume":"53","author":"JC Sebaaly","year":"2019","unstructured":"Sebaaly JC, Kelley D. HIV clinical updates: new single-tablet regimens. Ann Pharmacol. 2019;53(1):82\u201394.","journal-title":"Ann Pharmacol"},{"issue":"7","key":"1247_CR3","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1177\/1060028018758432","volume":"52","author":"R Boswell","year":"2018","unstructured":"Boswell R, Foisy MM, Hughes CA. Dolutegravir dual therapy as maintenance treatment in HIV-infected patients: a review. Ann Pharmacol. 2018;52(7):681\u20139.","journal-title":"Ann Pharmacol"},{"key":"1247_CR4","unstructured":"US Department of Health and Human Services Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV; 2019. http:\/\/adisinfo.nih.gov\/guidelines. Accessed 9 Sep 2019."},{"key":"1247_CR5","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s11904-018-0371-6","volume":"15","author":"Buckley R de Miguel","year":"2018","unstructured":"de Miguel Buckley R, Montejano R, Stella-Ascariz N, et al. New strategies of ARV: the road to simplification. Curr HIV\/AIDS Rep. 2018;15:11\u20139.","journal-title":"Curr HIV\/AIDS Rep"},{"issue":"1","key":"1247_CR6","first-page":"88","volume":"25","author":"A Kangethe","year":"2019","unstructured":"Kangethe A, Polson M, Lord TC, et al. Real-world healthplan data analysis: key trends in medication adherence and overall costs in patients with HIV. J Manag Care Spec Pharm. 2019;25(1):88\u201393.","journal-title":"J Manag Care Spec Pharm"},{"key":"1247_CR7","doi-asserted-by":"publisher","first-page":"475","DOI":"10.2147\/PPA.S192735","volume":"13","author":"F Altice","year":"2019","unstructured":"Altice F, Evuarherhe O, Shina S, et al. Adherence to HIV treatment regimens: systematic literature review and meta-analysis. Patient Prefer Adherence. 2019;13:475\u201390.","journal-title":"Patient Prefer Adherence"},{"key":"1247_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jgar.2019.08.010","author":"V Cento","year":"2019","unstructured":"Cento V, Perno CF. Two-drug regimens with dolutegravir plus rilpivirine or lamivudine in HIV-1 treatment-naive, virologically suppressed patients: latest evidences from the literature on their efficacy and safety. J Glob Antimicrob Resist. 2019. https:\/\/doi.org\/10.1016\/j.jgar.2019.08.010.","journal-title":"J Glob Antimicrob Resist"},{"key":"1247_CR9","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s12977-017-0360-7","volume":"14","author":"K Anstett","year":"2017","unstructured":"Anstett K, Brenner B, Mesplede T, et al. HIV drug resistance against strand transfer integrase inhibitors. Retrovirology. 2017;14:36.","journal-title":"Retrovirology"},{"key":"1247_CR10","unstructured":"European Medicines Agency. Dovato (dolutegravir\/lamivudine): summary of product characteristics; 2019. http:\/\/www.ema.europa.eu\/. Accessed 9 Sep 2019."},{"key":"1247_CR11","unstructured":"GlaxoSmithKline. DOVATO (dolutegravir and lamivudine tablets, for oral use): US prescribing information; 2019. http:\/\/www.gsksource.com\/. Accessed 9 Sep 2019."},{"issue":"11","key":"1247_CR12","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1007\/s40265-014-0256-y","volume":"74","author":"PL McCormack","year":"2014","unstructured":"McCormack PL. Dolutegravir: a review of its use in the management of HIV-1 infection in adolescents and adults. Drugs. 2014;74(11):1241\u201352.","journal-title":"Drugs"},{"key":"1247_CR13","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1124\/mol.111.073189","volume":"80","author":"S Hare","year":"2011","unstructured":"Hare S, Smith SJ, M\u00e9tifiot M, et al. Structural and functional analyses of the second-generation integrase strand inhibitor dolutegravir (S\/GSK1349572). Mol Pharmacol. 2011;80:565\u201372.","journal-title":"Mol Pharmacol"},{"key":"1247_CR14","doi-asserted-by":"publisher","first-page":"2412","DOI":"10.1093\/jac\/dku144","volume":"69","author":"M Pollicita","year":"2014","unstructured":"Pollicita M, Surdo M, Di Santo F, et al. Comparative replication capacity of raltegravir-resistant strains and antiviral activity of the new generation integrase inhibitor dolutegravir in human primary macrophages and lymphocytes. J Antimicrob Chemother. 2014;69:2412\u20139.","journal-title":"J Antimicrob Chemother"},{"issue":"2","key":"1247_CR15","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1128\/AAC.01209-10","volume":"55","author":"M Kobayashi","year":"2011","unstructured":"Kobayashi M, Yoshinaga T, Seki T, et al. In vitro antiretroviral properties of S\/GSK1349572, a next-generation HIV integrase inhibitor. Antimicrob Agents Chem. 2011;55(2):813\u201321.","journal-title":"Antimicrob Agents Chem"},{"issue":"8","key":"1247_CR16","doi-asserted-by":"publisher","first-page":"2365","DOI":"10.1093\/jac\/dkz190","volume":"74","author":"J Gillman","year":"2019","unstructured":"Gillman J, Janulis P, Gulick R, et al. Comparable viral decay with initial dolutegravir plus lamivudine versus dolutegravir-based triple therapy. J Antimicrob Chemother. 2019;74(8):2365\u20139.","journal-title":"J Antimicrob Chemother"},{"issue":"10","key":"1247_CR17","doi-asserted-by":"publisher","first-page":"4552","DOI":"10.1128\/AAC.00157-11","volume":"35","author":"KE Hightower","year":"2011","unstructured":"Hightower KE, Wang R, DeAnda F, et al. Dolutegravir (S\/GSK1349572) exhibits significantly slower dissociation than raltegravir or elvitegravir from wild-type and integrase inhibitor-resistant HIV-1 integrase-DNA complexes. Antimicrob Agents Chem. 2011;35(10):4552\u20139.","journal-title":"Antimicrob Agents Chem"},{"issue":"10","key":"1247_CR18","doi-asserted-by":"publisher","first-page":"e77448","DOI":"10.1371\/journal.pone.0077448","volume":"8","author":"F DeAnda","year":"2013","unstructured":"DeAnda F, Hightower KE, Nolte RT, et al. Dolutegravir interactions with HIV-1 integrase-DNA: structural rationale for drug resistance and dissociation kinetics. PLoS One. 2013;8(10):e77448.","journal-title":"PLoS One"},{"key":"1247_CR19","unstructured":"European Medicines Agency. Trivacy (dolutegravir): summary of product characteristics; 2019. http:\/\/www.ema.europa.eu\/. Accessed 23 Sep 2019."},{"key":"1247_CR20","doi-asserted-by":"publisher","first-page":"3135","DOI":"10.1093\/jac\/dkz256","volume":"74","author":"S-Y Rhees","year":"2019","unstructured":"Rhees S-Y, Grant PM, Tzou PL, et al. A systematic review of the genetic mechanisms of dolutegravir resistance. J Antimicrob Chemother. 2019;74:3135\u201349.","journal-title":"J Antimicrob Chemother"},{"issue":"10167","key":"1247_CR21","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/S0140-6736(18)32462-0","volume":"393","author":"P Cahn","year":"2019","unstructured":"Cahn P, Madero JS, Arribas JR, et al. Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials. Lancet. 2019;393(10167):143\u201355.","journal-title":"Lancet"},{"issue":"Suppl 5","key":"1247_CR22","first-page":"103","volume":"22","author":"P Cahn","year":"2019","unstructured":"Cahn P, Sierra Madero J, Arribas J, et al. Durable efficacy of dolutegravir (DTG) plus lamivudine (3TC) in antiretroviral treatment-na\u00efve adults with HIV-1 infection\u201496-week results from the GEMINI studies [abstract no. WEAB0404LB]. J Int AIDS Soc. 2019;22(Suppl 5):103.","journal-title":"J Int AIDS Soc"},{"key":"1247_CR23","unstructured":"van Wyk J, Ajana F, Bisshop F, et al. Switching to DTG\/3TC fixed dose combination (FDC) is non-inferior to continuing a TAF-based regimen in maintaining virologic suppression through 48\u00a0weeks (TANGO Study) [oral presentation]. In: 10th IAS conference on HIV science; 2019. http:\/\/www.ias2019.org\/Programme. Accessed 11 Sep 2019."},{"key":"1247_CR24","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1093\/jac\/dku535","volume":"70","author":"S Fourati","year":"2015","unstructured":"Fourati S, Charpentier C, Amiel C, et al. Cross-resistance to elvitegravir and dolutegravir in 502 patients failing on raltegravir: a French national study of raltegravir-experienced HIV-1 infected patients. J Antimicrob Chemother. 2015;70:1507\u201312.","journal-title":"J Antimicrob Chemother"},{"issue":"21678","key":"1247_CR25","first-page":"1","volume":"20","author":"P Cahn","year":"2017","unstructured":"Cahn P, Rolon MJ, Figueroa MI, et al. Dolutegravir-lamivudine as initial therapy in HIV-1 infected, ARV-naive patients, 48-week results of the PADDLE (Pilot Antiretroviral Design with Dolutegravir LamivudinE) study. J Int AIDS Soc. 2017;20(21678):1\u20137.","journal-title":"J Int AIDS Soc"},{"issue":"11","key":"1247_CR26","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1093\/cid\/cix1083","volume":"66","author":"BO Taiwo","year":"2018","unstructured":"Taiwo BO, Zheng L, Stefanescu A, et al. ACTG A5353: a pilot study of dolutegravir plus lamivudine for initial treatment of human immunodeficiency virus-1 (HIV-1)-infected participants with HIV-1 RNA <500000 copies\/mL. Clin Infect Dis. 2018;66(11):1689\u201397.","journal-title":"Clin Infect Dis"},{"issue":"5","key":"1247_CR27","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1093\/jac\/dky564","volume":"74","author":"AN Nyaku","year":"2019","unstructured":"Nyaku AN, Zheng L, Gulick RM, et al. Dolutegravir plus lamivudine for initial treatment of HIV-1-infected participants with HIV-1 RNA <500 000 copies\/mL: week 48 outcomes from ACTG 5353. J Antimicrob Chemother. 2019;74(5):1376\u201380.","journal-title":"J Antimicrob Chemother"},{"key":"1247_CR28","unstructured":"Underwood M, Wang R, Horton J, et al. Dolutegravir (DTG) plus lamivudine (3TC) versus DTG plus tenofovir\/emtricitabine (TDF\/FTC) fixed-dose combination in the GEMINI studies: viral load rebound including\u201a blips\u2019 through 48 weeks [abstract no. MOPEB231]. In: 10th IAS conference on HIV science; 2019."},{"issue":"11","key":"1247_CR29","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1097\/QAD.0000000000002285","volume":"33","author":"M Radford","year":"2019","unstructured":"Radford M, Parks DC, Ferrante S, et al. Comparative efficacy and safety and dolutegravir and lamivudine in treatment naive HIV patients. AIDS. 2019;33(11):1739\u201349.","journal-title":"AIDS"},{"issue":"Suppl 5","key":"1247_CR30","first-page":"102","volume":"22","author":"J van Wyk","year":"2019","unstructured":"van Wyk J, Ajana F, Bisshop F, et al. Switching to DTG+3TC fixed dose combination (FDC) is non-inferior to continuing a TAF-based regimen (TBR) in maintaining virologic suppression through 24 weeks (TANGO Study) [abstract no. WEAB0403LB]. J Int AIDS Soc. 2019;22(Suppl 5):102\u20133.","journal-title":"J Int AIDS Soc"},{"issue":"7","key":"1247_CR31","doi-asserted-by":"publisher","first-page":"1965","DOI":"10.1093\/jac\/dky093","volume":"73","author":"JL Blanco","year":"2018","unstructured":"Blanco JL, Rojas J, Paredes R, et al. Dolutegravir-based maintenance monotherapy versus dual therapy with lamivudine: a planned 24 week analysis of the DOLAM randomized clinical trial. J Antimicrob Chemother. 2018;73(7):1965\u201371.","journal-title":"J Antimicrob Chemother"},{"issue":"3","key":"1247_CR32","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1093\/jac\/dky467","volume":"74","author":"V Joly","year":"2019","unstructured":"Joly V, Burdet C, Landman R, et al. Dolutegravir and lamivudine maintenance therapy in HIV-1 virologically suppressed patients: results of the ANRS 167 trial (LAMIDOL). J Antimicrob Chemother. 2019;74(3):739\u201345.","journal-title":"J Antimicrob Chemother"},{"issue":"11","key":"1247_CR33","doi-asserted-by":"publisher","first-page":"1794","DOI":"10.1093\/cid\/cix1131","volume":"66","author":"BO Taiwo","year":"2018","unstructured":"Taiwo BO, Marconi VC, Berzins B, et al. Dolutegravir plus lamivudine maintains human immunodeficiency virus-1 suppression through week 48 in a pilot randomized trial. Clin Infect Dis. 2018;66(11):1794\u20137.","journal-title":"Clin Infect Dis"},{"issue":"5","key":"1247_CR34","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1093\/jac\/dkz009","volume":"74","author":"G Baldin","year":"2019","unstructured":"Baldin G, Ciccullo A, Borghetti A, et al. Virological efficacy of dual therapy with lamivudine and dolutegravir in HIV-1-infected virologically suppressed patients: long-term data from clinical practice. J Antimicrob Chemother. 2019;74(5):1461\u20133.","journal-title":"J Antimicrob Chemother"},{"key":"1247_CR35","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.eclinm.2018.11.005","volume":"6","author":"ND Diaco","year":"2018","unstructured":"Diaco ND, Strickler C, Giezendanner S, et al. Systematic de-escalation of successful triple antiretroviral therapy to dual therapy with dolutegravir plus emtricitabine or lamivudine in Swiss HIV-positive persons. EClinicalMedicine. 2018;6:21\u20135.","journal-title":"EClinicalMedicine"},{"issue":"59","key":"1247_CR36","first-page":"1","volume":"19","author":"A Borghetti","year":"2019","unstructured":"Borghetti A, Lombardi F, Gagliardini R, et al. Efficacy and tolerability of lamivudine plus dolutegravir compared with lamivudine plus boosted PIs in HIV-1 positive individuals with virologic suppression: a retrospective study from the clinical practice. BMC Infect Dis. 2019;19(59):1\u20139.","journal-title":"BMC Infect Dis"},{"issue":"1","key":"1247_CR37","doi-asserted-by":"publisher","first-page":"63","DOI":"10.3851\/IMP3270","volume":"24","author":"A Ciccullo","year":"2019","unstructured":"Ciccullo A, Baldin G, Capetti A, et al. A comparison between two dolutegravir-based two-drug regimens as switch strategies in a multicentre cohort of HIV-1-infected patients. Antivir Ther. 2019;24(1):63\u20137.","journal-title":"Antivir Ther"},{"issue":"215","key":"1247_CR38","first-page":"1","volume":"17","author":"F Maggiolo","year":"2017","unstructured":"Maggiolo F, Gulminetti R, Pagnucco L, et al. Lamivudine\/dolutegravir dual therapy in HIV-infected, virologically suppressed patients. BMC Infect Dis. 2017;17(215):1\u20137.","journal-title":"BMC Infect Dis"},{"issue":"32","key":"1247_CR39","doi-asserted-by":"publisher","first-page":"e16813:1\u20137","DOI":"10.1097\/MD.0000000000016813","volume":"98","author":"C Hidalgo-Tenorio","year":"2019","unstructured":"Hidalgo-Tenorio C, Cortes LL, Gutierrez A, et al. DOLAMA study: effectiveness, safety and pharmacoeconomic analysis of dual therapy with dolutegravir and lamivudine in virologically suppressed HIV-1 patients. Medicine (Baltimore). 2019;98(32):e16813:1\u20137.","journal-title":"Medicine (Baltimore)"},{"issue":"Suppl 3","key":"1247_CR40","doi-asserted-by":"publisher","first-page":"S231","DOI":"10.1016\/j.jval.2018.09.1383","volume":"21","author":"T Ward","year":"2018","unstructured":"Ward T, Punekar YS, Darlington O, et al. Dolutegravir plus lamivudine for the treatment of naive adults living with HIV-1: a UK cost-minimization analysis [abstract no. PIN64]. Value Health. 2018;21(Suppl 3):S231\u20132.","journal-title":"Value Health"},{"issue":"Suppl 8","key":"1247_CR41","first-page":"113","volume":"21","author":"M Piscaglia","year":"2018","unstructured":"Piscaglia M, Gallazzi I, Restelli S, et al. Impact on bone mineral density after 2 years of switching to four dolutegravir-based triple or dual regimens [abstract no. P162]. J Int AIDS Soc. 2018;21(Suppl 8):113\u20134.","journal-title":"J Int AIDS Soc"},{"issue":"4","key":"1247_CR42","first-page":"336","volume":"26","author":"A Ciccullo","year":"2018","unstructured":"Ciccullo A, D\u2019Avino A, Lassandro AP, et al. Changes in bone mineral density in HIV-positive, virologically suppressed patients switching to lamivudine\/dolutegravir dual therapy: preliminary results from clinical practice. Infez Med. 2018;26(4):336\u201340.","journal-title":"Infez Med"},{"key":"1247_CR43","unstructured":"European AIDS Clinical Society. EACS guidelines version 10.0 November 2019; 2019. http:\/\/eacsociety.org. Accessed 10 Dec 2019."},{"key":"1247_CR44","unstructured":"World Health Organization. Updated recommendations on first-line and second-line antiretroviral regimens and post-exposure prophylaxis and recommendations on early infant diagnosis of HIV; 2018. http:\/\/www.who.int\/. Accessed 9 Sep 2019."},{"key":"1247_CR45","unstructured":"British HIV Association. BHIVA treatment guidelines: 2019 interim statement on two-drug regimens; 2019. http:\/\/www.bhiva.org\/HIV-1-treatment-guidelines. Accessed 22 Nov 2019."},{"key":"1247_CR46","doi-asserted-by":"publisher","DOI":"10.1089\/AID.2019.0171","author":"M Boffito","year":"2019","unstructured":"Boffito M, Waters L, Cahn P, et al. Perspectives on the barrier to resistance for dolutegravir + lamivudine, a 2-drug antiretroviral therapy for HIV-1 infection. AIDS Res Hum Retroviruses. 2019. https:\/\/doi.org\/10.1089\/AID.2019.0171.","journal-title":"AIDS Res Hum Retroviruses"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-019-01247-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-019-01247-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-019-01247-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T16:51:49Z","timestamp":1659113509000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-019-01247-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,21]]},"references-count":46,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["1247"],"URL":"https:\/\/doi.org\/10.1007\/s40265-019-01247-1","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12,21]]},"assertion":[{"value":"21 December 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The preparation of this review was not supported by any external funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Lesley Scott is a salaried employee of Adis International Ltd\/Springer Nature, is responsible for the article content and declares no relevant conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}